Protelica, Inc.

Pfizer Corporation

Creatrone, Inc.

Bioren, Inc.

Protelix, Inc.

Guido Cappuccilli

Roberto Crea

Randy Shen

Craig A Hokanson

David R Liston

Peter B Kirk

Arvind Rajpal

Toshihiko Takeuchi

Ramesh Bhatt

Nurten Beyaz-Kavuncu

Takeuchi Toshihilo

Universal antibody libraries are described which are synthetic and derived from expressed human antibody sequences selected accordingly to certain criteria, for example, that the sequences are derived from naturally-occurring antibodies expressed in response to a certain antigen class (e.g., small molecule, polysaccharide, peptide, or protein) and having CDR regions engineered for optimal diversity. Methods for making and screening such libraries for isolating therapeutics suitable for treating disease are also disclosed.

Universal antibody libraries

Fibronectin Type III (FN3) polypeptide libraries are described, along with their use in identifying fibronectin-type binding peptides having high binding affinities, e.g., greater than 300 nM, for VEGFR2 or Axl proteins.

Universal fibronectin type III binding-domain libraries

A composition comprising individual single-stranded oligonucleotides capable of self assembling to form a pair of complementary, substantially contiguous single strands of a double-stranded nucleic acid filament, and a method for forming such filaments are disclosed.

Self-assembling oligonucleotides and methods

Methods and compositions directed to improved universal antibody libraries that rationally exploit human diversity information contained within reference antibody libraries, such as universal antibody libraries, are disclosed. The disclosed processes involve use of a query CDR sequence to guide incorporation of human antibody diversity present within the reference library into cohort libraries of the invention. Methods for making and screening such cohort libraries for isolating therapeutics suitable for treating disease are also disclosed.

Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening

Walk-through mutagenesis and natural-variant combinatorial fibronectin Type III (FN3) polypeptide libraries are described, along with their method of construction and use. Also disclosed are a number of high binding affinity polypeptides selected by screening the libraries against a variety of selected antigens.

Universal fibronectin Type III binding-domain libraries

Growing community of inventors

San Mateo, CA, United States of America

Guido Cappuccilli